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Lectin-like oxidized low-density lipoprotein receptor-
1 (LOX-1) is a pattern-recognition receptor for a
variety of endogenous and exogenous ligands. How-
ever, LOX-1 function in the host immune response is
not fully understood. Here, we report that LOX-1 ex-
pressedondendritic cells (DCs) andBcells promotes
humoral responses. On B cells LOX-1 signaling upre-
gulated CCR7, promoting cellular migration toward
lymphoid tissues. LOX-1 signaling on DCs licensed
the cells to promote B cell differentiation into class-
switched plasmablasts and led to downregulation
of chemokine receptor CXCR5 and upregulation
of chemokine receptor CCR10 on plasmablasts,
enabling their exit from germinal centers and migra-
tion toward local mucosa and skin. Finally, we
found that targeting influenza hemagglutinin 1 (HA1)
subunit to LOX-1 elicited HA1-specific protec-
tive antibody responses in rhesus macaques. Thus,
LOX-1 expressed on B cells and DC cells has com-
plementary functions to promote humoral immune
responses.
INTRODUCTION
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is
a pattern-recognition receptor (PRR) (Huysamen and Brown,
2009). LOX-1 is expressed on the surface of endothelial cells,
smooth muscle cells, platelets, fibroblasts, dendritic cells
(DCs), B cells, and macrophages (Delneste et al., 2002; Dunn
et al., 2008; Huysamen and Brown, 2009; Jeannin et al., 2005;
Li et al., 2012; Nickel et al., 2009). LOX-1 expression can be
regulated by a variety of stimuli, including proinflammatory and
inflammatory cytokines (Chen et al., 2007; Dunn et al., 2008).
LOX-1 also belongs to the scavenger receptor family and can
recognize both endogenous and exogenous ligands, including
modified lipoproteins such as oxidized-LDL (ox-LDL), as well
as apoptotic cells, activated platelets and certain bacteria (Huy-592 Immunity 41, 592–604, October 16, 2014 ª2014 Elsevier Inc.samen and Brown, 2009; Kakutani et al., 2000; Oka et al., 1998;
Parlato et al., 2010; Shimaoka et al., 2001).
The involvement of LOX-1 in host immune responses, espe-
cially T cell responses, was previously reported (Delneste
et al., 2002; Jeannin et al., 2005; Parlato et al., 2010). LOX-1 ex-
pressed on DCs can capture bacterial components, which then
colocalize with Toll-like receptor 2 (TLR2) to activate DCs, lead-
ing to enhanced cellular responses (Jeannin et al., 2005). In addi-
tion, antigen delivered to mouse DCs via LOX-1 using antigen
conjugated to either anti-mouse LOX-1 (Delneste et al., 2002)
or heat shock protein 70 (HSP70) (Xie et al., 2010) elicited anti-
gen-specific CD8+ T cell responses. Parlato et al. (2010)
also showed that human monocyte-derived DCs capture anti-
gens via LOX-1 and cross-present them to CD8+ T cells. More
recently, we have shown that targeting antigens to DCs via
LOX-1 can elicit antigen-specific T cell responses (Li et al., 2012).
In consideration of its wide expression and the currently
known biological functions of LOX-1 as a c-type lectin-like
PRR, we surmised that LOX-1 could have many more diverse
functions in host immune responses. Although LOX-1 expres-
sion on DCs and B cells is known, the role of LOX-1 in humoral
immune responses remains unknown. We therefore explored
functions of LOX-1 expressed on DCs and B cells in humoral
responses. DCs are major antigen-presenting cells that can
induce and control the quantity and quality of cellular immune re-
sponses. DCs also play an important role in both T-dependent
(TD) and T-independent (TI) humoral responses.
In this study,we found that LOX-1 canprogramDCsandBcells
to promote class-switched antibody (Ab) responses. This unique
ability of LOX-1makes it standout fromother lectin-like receptors.
We have also investigated the mechanisms by which LOX-1 pro-
motes DC-mediated class-switched B cell responses. Finally, we
tested whether targeting influenza HA1 antigen to LOX-1 could
elicit HA1-specific protective Ab responses in rhesus macaques.
RESULTS
aLOX-1-Treated DCs Promote BCell Differentiation into
Plasmablasts
To study the biology of human LOX-1 (hLOX-1), we gener-
ated an aLOX-1 (clone 8B4; immunoglobulin G1k [IgG1k])
A B
C
D E
F
G
H
Figure 1. LOX-1 Promotes DC-Mediated PB Differentiation and Antibody Responses
(A) Binding of aLOX-1 mAb to CD11c+, CD14+, CD19+, and CD3+ cells in PBMCs from healthy donors.
(B) Immunofluorescence of spleens. Frozen sections of human spleens were stained for aCD11c (green), aLOX-1 (red), aIgD (blue). The outlined area on the left
corresponds to the enlargement on the right. Original magnification, 103 (left) or 633 (right).
(C) LOX-1 expression on in vitro monocyte-derived IL-4 DCs.
(D) Different numbers of IL-4 DCs were incubated overnight in plates coated with 2 mg/ml aLOX-1 (8B4) or control IgG. 1–2 3 105 CFSE-labeled CD19+ B cells
were cocultured for 12 days in the presence of IL-2. Concentrations of Ig in the culture supernatants were assessed by sandwich ELISA. Error bars indicate SD of
triplicate assay. Three independent experiments using cells from three healthy donors resulted in similar data.
(E) On day 6 of the culture in (D), CD38 expression and CFSE dilution were measured (left). CD19+CFSECD38+ B cells were FACS-sorted and cell morphology
was examined (middle). B cells were also stained for CD20 (right).
(F) DC and B cell cocultures in (D) were performed in transwells or single wells. CD38 expression and CFSE dilution were assessed. Numbers of CD38+CD20 B
cells were assessed using counting beads. Four independent experiments using cells from two healthy donors were performed. Error bars indicate SD.
(G) On day 6 of the culture in (D), surface expression of CD38 and CD20 on B cells were assessed. Expression of intracellular Pax5 and Blimp-1 was measured.
Three independent experiments using cells from different healthy donors showed similar results.
(H) 53 103 IL-4 DCswere cultured overnight in plates coatedwith aLOX-1 (8B4) or control IgG. The amount of IL-6 in the culture supernatants was analyzed by the
BeadLyte assay kit (left). Error bars indicate SD of three independent experiments using cells from different donors. Purified CD19+ B cells were incubated in the
culture supernatant of aLOX-1- or control IgG-treated DCs for 15 min (right). Cells were lysed and used for immunoblot analysis of STAT3 and phospho-STAT3
(pSTAT3).
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LOX-1 Promotes Class-Switched B Cell Responsesmonoclonal antibody (mAb) specific for the ectodomain of
hLOX-1, as previously described (Li et al., 2012). The speci-
ficity of aLOX-1 mAb was tested by staining 293F cells
transfected with a full-length hLOX-1 expression vector (see
Figure S1A and S1B available online). This was confirmed by
the data showing that aLOX-1 mAb bound to a recombinant
hLOX-1 ectodomain-Fc, but not a control fusion protein
(human dendritic cell immunoreceptor [hDCIR] ectodomain-
Fc fusion; Figure S1C).aLOX-1 mAb bound to fractions of CD11c+, CD14+, and
CD19+, but not CD3+ T cells, in peripheral blood mononuclear
cells (PBMCs) (Figure 1A). hLOX-1 was not expressed in human
plasmacytoid DCs (pDCs) (Li et al., 2012). We also found that
many of the CD11c+ cells localized at marginal zones and extra-
follicular areas in human spleen expressed LOX-1 (Figure 1B;
Figure S1D). Interestingly, CD11c+LOX-1+ cells in the marginal
zone interacted with IgD+ B cells, suggesting that LOX-1 on
DCs could contribute to humoral responses.Immunity 41, 592–604, October 16, 2014 ª2014 Elsevier Inc. 593
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LOX-1 Promotes Class-Switched B Cell ResponsesWe next tested the roles of LOX-1 in DC-mediated B cell re-
sponses. Interleukin-4 (IL-4) DCs were generated by culturing
monocytes in the presence of GM-CSF and IL-4. IL-4 DCs ex-
pressed surface LOX-1 (Figure 1C). Different numbers of IL-4
DCswere incubated overnight in the presence of aLOX-1 or con-
trol IgG. CFSE-labeled CD19+ total B cells were then cocultured
for 12 days in the presence of IL-2. Figure 1D shows that B cells
cocultured with aLOX-1-treated DCs secreted greater amounts
of IgM, IgG, and IgA than B cells cocultured with control IgG-
treated DCs. Furthermore, the amounts of IgM, IgG, and IgA in
the supernatants correlated with the numbers of DCs in the cul-
ture. In addition, aLOX-1-treated DCs were more efficient than
control IgG-treated DCs at inducing B cell proliferation and
CD38+CD20 plasmablast (PB) differentiation (Figure 1E). These
PBs displayed eccentric nuclei, which is a typical morphology of
plasma cells, but they did not express CD138 (Figure S1E). Fig-
ure 1F shows that intercellular interactions between aLOX-1-
treated DCs and B cells are important for PB differentiation. In
addition to IL-4 DCs, interferon (IFN) DCs generated by culturing
monocytes in thepresenceofGM-CSFand IFN-a also expressed
LOX-1, but tumor necrosis factor (TNF) DCs generated with GM-
CSF and TNF-a did not (upper left, Figure S1F). aLOX-1-treated
IFN DCs also enhanced PB differentiation (lower left, Figure S1F)
and Ig secretion (right, Figure S1F). aLOX-1mAbwas also able to
promote PB differentiation (left, Figure S1G) and Ig secretion
(right, Figure S1G) from B cells in PBMC cultures.
Taken together, aLOX-1-treated DCs can promote B cell re-
sponses by enhancing PB differentiation and Ig secretion. In
addition, intercellular interactions between aLOX-1-treated DCs
and B cells play an important role in enhancing B cell responses.
aLOX-1-Treated DCs Control Expression of Pax5 and
Blimp-1 Transcription Factors to Generate PBs
Both paired box 5 (Pax5) and B lymphocyte-induced maturation
protein 1 (Blimp-1) play important roles in B cell differentiation
into plasma cells (Martins and Calame, 2008). B cells cocultured
with aLOX-1-treated DCs downregulated Pax5, but upregulated
Blimp-1 expression (Figure 1G). Furthermore, aLOX-1-treated
DCs secreted IL-6 (left, Figure 1H). In addition, B cells incubated
in the culture supernatant of aLOX-1-treated DCs showed more
signal transducer and activator of transcription 3 (STAT3) phos-
phorylation than B cells incubated in the culture supernatant of
control IgG-treated DCs (right, Figure 1H). STAT3 activation
is involved in plasma cell differentiation by inducing Blimp-1
expression in B cells (Diehl et al., 2008). aLOX-1-treated DCs
did not secrete IL-4, IL-10, or type 1 IFN. Taken together, the
enhanced PB differentiation by aLOX-1-treated DCs is sup-
ported by Pax5 downregulation and Blimp-1 upregulation along
with STAT3 activation in B cells.
B Cells Express Functional LOX-1
Total (CD19+), naive (CD19+IgD+CD27), and memory B cells
(CD19+IgDCD27+ and CD19+IgD+CD27+) in peripheral blood
expressed similar amounts of surface LOX-1 (Figure 2A). How-
ever, LOX-1 expression on total B cells was downregulated
by aBCR, aCD40, and CpG treatments (Figure 2B). Figure 2C
shows that aLOX-1 mAb alone did not promote PB differentia-
tion, as measured by CD38 expression, with minimal B cell pro-
liferation. However, it did induce B cells to secrete some IgM and594 Immunity 41, 592–604, October 16, 2014 ª2014 Elsevier Inc.IgG, but minimal IgA (Figure 2D), although IgM and IgG concen-
trations in the supernatants of B cell cultures (Figure 2D) were
much lower than those observed in the supernatants of B cells
cocultured with DCs (Figure 1D).
To further investigate the immunological function of LOX-1
expression on B cells, we cultured total B cells overnight with
aLOX-1 or control IgG and then stained for CD40, C-X-C chemo-
kine receptor type 5 (CXCR5), chemokine receptor 6 (CCR6), and
chemokine receptor 7 (CCR7) (Figure 2E). aLOX-1 mAb slightly
upregulated both CCR6 and CXCR5, which could contribute
to B cell migration into and retention within germinal centers
(GCs). B cells incubated with aLOX-1 mAb expressed CCR7, a
lymphoid organ homing receptor. B cells cultured with aLOX-1
mAb also migrated more efficiently toward chemokine ligand
19 (CCL19) than B cells cultured with control IgG (Figure 2F).
The two groups of B cells did not respond to chemokine ligand
27 (CCL27), a ligand for chemokine receptor 10 (CCR10). Collec-
tively, LOX-1 expressed on B cells is functional and could there-
fore contribute to humoral immune responses.
LOX-1 Programs DCs to Induce Naive B Cell
Differentiation into Class-Switched PBs
Although IgG and IgA class-switching can occur in a TI manner at
local tissues, including mucosa (Fagarasan et al., 2001; He et al.,
2007;Macphersonet al., 2000;Uematsuet al., 2008), TDGC reac-
tionsarecentral for clonal expansion, Igclass-switching, andhigh-
affinity plasma cell generation (Liu and Arpin, 1997). Thus, we
tested whether LOX-1 on DCs could promote naive B cell differ-
entiation into IgG- and IgA-secreting PBs in a TD manner. CFSE-
labeled naive B cells (CD19+IgD+CD27) were cocultured for
6 dayswith aLOX-1- or control IgG-treatedDCs. In order tomimic
a TDBcell response, naiveB cellswere activatedwith a combina-
tion of aBCR,CpG (TLR9 engagement bymicrobial DNA), aCD40,
and IL-2 (cognate interactionswithCD4+ T cells). DCs treatedwith
2mg/mlaLOX-1 inducedgreater naiveBcell proliferation thanDCs
treated with 2 mg/ml control IgG. The aLOX-1-treated DCs also
induced greater PB (CD38+CD20) differentiation (Figure 3A).
These PBs also expressed decreased amounts of HLA-DR (Fig-
ure S2A) (Joo et al., 2012). Naive B cell differentiation into PBs
was also dependent on the amount of aLOX-1 mAb. PB differen-
tiation data from four independent experiments with 2 mg/ml
aLOX-1 or control IgG are summarized in Figure 3B. Without
DCs,naiveBcell differentiation intoPBswasminimal (FigureS2B).
Consistent with the PB differentiation data, aLOX-1-treated
DCs resulted in greater amounts of both IgM and IgG than did
control IgG-treated DCs (upper, Figure 3C). Naive B cells cocul-
tured with control IgG-treated DCs secreted low or minimal
amounts of IgA1 and IgA2, whereas aLOX-1-treated DCs greatly
enhanced both IgA1 and IgA2 secretion from B cells (lower, Fig-
ure 3C). Data in Figure S2C further demonstrate the correlation
between the amount of Igs and the concentrations of aLOX-1
mAb. Thus, LOX-1 plays an important role in enhanced B cell
responses by promoting naive B cell differentiation into PBs
that secrete class-switched Igs.
Quantitative real-time RT-PCR data showed that naive B cells
cocultured with aLOX-1-treated DCs induced increased AICDA
expression, a hallmark of B cells undergoing active class-switch-
ing (Muramatsu et al., 2000), than B cells cocultured with control
IgG-treated or untreated DCs (Figure 3D). Figure 3E shows that
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Figure 2. Human B Cells Express Functional LOX-1
(A) LOX-1 expression on peripheral B cell subsets.
(B) Purified total B cells were cultured overnight in the presence or absence of 10 mg/ml aIgM, 100 ng/ml aCD40, or 50 nMCpGODN2006. LOX-1 expression was
assessed.
(C) Purified and CFSE-labeled total B cells were cultured in plates coated with aLOX-1 or control IgG for 7 days. Cells were stained with CD19 and CD38.
(D) On day 12 of the B cell culture in (C), culture supernatants were analyzed for measuring Igs by ELISA.
(E) Purified total B cells were cultured overnight in plates coated with aLOX-1 or control IgG. B cells were stained for CD40, CCR6, CXCR5, and CCR7.
(F) B cells in (E) were added to the upper wells of transwells containing the indicated concentrations of CCL27 or CCL19 in the lower wells. After 2 hr, the number of
cells that migrated into the lower wells was determined using counting beads. Two independent experiments using cells from two different donors showed similar
results.
In (D) and (F), error bars indicate mean ± SD of triplicate assays in individual experiments.
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LOX-1 Promotes Class-Switched B Cell Responsesnaive B cells cocultured with aLOX-1-treated DCs expressed
increased Ig-Cm and Ia-Cm switch circle transcripts. Naive B
cells cocultured with aLOX-1-treated DCs also expressed higher
amounts of germline andmature transcripts for IgA1, IgA2, IgG1-
4, and IgM (Figure 3F). Taken together, LOX-1 can program DCs
to promote naive B cell proliferation, PB differentiation, and Ig
class-switching.
aLOX-1-Treated DCs Upregulate CCR10 but
Downregulate CXCR5 Expression on B Cells
We next measured expression of chemokine receptors on B cells
coculturedwith theDCs.aLOX-1-treatedDCs induced20%–30%
of activated naive B cells to express CCR10 (Figures 4A and 4B).
The induced CCR10 was functional as the B cells migrated, in a
chemotaxis assay, toward the two CCR10 ligands: CCL28 andCCL27 (Figure 4C). There was no upregulation of CCR6, CCR9,
or b7 integrin (Figure S3). Consequently, naive B cells cultured
with aLOX-1-treated DCs did not migrate in response to CCL25,
a ligand for CCR9. CFSECCR10+ B cells induced with aLOX-1-
treatedDCsexpressed lessCXCR5 thandidCFSE+CCR10naive
B cells in the same cultures (Figure 4D). Thus, upregulation of
CCR10, along with downregulation of CXCR5, could allow PBs
to migrate out of the GCs en route to mucosal sites. This is sup-
ported by our previous study, showing that the majority of IgA+
cells in a tonsil GCs express CCR10 (Dullaers et al., 2009).
LOX-1-Activated DCs Secrete TNF Family Ligands to
Promote IgA- and IgG-Secreting B Cell Responses
To further investigate the mechanisms by which aLOX-1-treated
DCs promote IgA and IgG responses, we analyzed overnightImmunity 41, 592–604, October 16, 2014 ª2014 Elsevier Inc. 595
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Figure 3. LOX-1 Promotes Naive B Cell Differentiation into PBs and Ig Class-Switching
(A) IL-4 DCs (5 3 103/well) were incubated overnight in plates coated with aLOX-1 or control IgG. CFSE-labeled naive B cells (1 3 105, CD19+IgD+CD27) were
stimulated with aIgM and then cocultured with the DCs in the presence of 20 units/ml IL-2, 50 nM CpG, and 100 ng/ml agonistic aCD40 mAb. On day 6, B cells
were stained with CD38 and CD20. Four independent experiments using cells from different donors showed similar results.
(B) Summary of PB differentiation from four independent experiments in (A). Error bars indicate SD.
(C) Culture supernatants in (A) and (B) were harvested on day 12 and the amounts of Igs were measured by ELISA. Error bars indicate SD.
(D–F) Naive B cells coculturedwith theDCs (A) were harvested on day 4. Real time RT-PCRwas performed for activation-induced cytidine deaminase (AICDA) (D),
switch-circle transcripts Ig-Cm and Ia-Cm (E), germline (left), and mature transcripts (right) (F). The expression of AICDA was normalized to ACTB expression.
Ig-Cm and Ia-Cm expression was normalized to Im-Cm expression (He et al., 2007). Data shown are mean ± SD of three independent experiments using cells from
two different healthy donors. PCR products of the germline mature transcripts were analyzed on agarose gels.
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LOX-1 Promotes Class-Switched B Cell Responsesculture supernatants of DCs for the amounts of a proliferation-
inducing ligand (APRIL) and B cell-activating factor (BAFF),
cytokines that promote B cell proliferation, differentiation, class-
switching, and plasma cell survival (Cerutti, 2008; Joo et al.,
2012; Litinskiy et al., 2002; Xu et al., 2007). Both IL-4 DCs (Fig-
ure 5A) and blood myeloid DCs (mDCs) (Figure 5E) secreted
APRIL and BAFF, but not TGF-b (data not shown), in response
to aLOX-1 mAb.
To test the roles of APRIL and BAFF in the aLOX-1-activated
DC-mediated B cell responses, recombinant proteins that
neutralize APRIL and BAFF were added to cocultures. Trans-
membrane activator and calcium-modulator and cytophilin
ligand interactor-Fc (TACI-Fc) and B cell maturation antigen-Fc
(BCMA-Fc) (which can neutralize both APRIL and BAFF) or
aBAFF Ab (which neutralizes BAFF) were added at the beginning
of cocultures of aLOX-1-activated DCs and naive B cells. After
12 days, concentrations of Ig in culture supernatants were
measured by ELISA (Figures 5B and 5F). Compared to control
antibody, both TACI-Fc and BCMA-Fc significantly reduced
IgM and IgA concentrations, but BCMA-Fc was more efficient
than TACI-Fc, particularly for IgM and IgA2. aBAFF Ab596 Immunity 41, 592–604, October 16, 2014 ª2014 Elsevier Inc.decreased IgG secretion, but not IgM or IgA secretion. Data
generated with either IL-4 DCs (Figure 5B) or blood mDCs
gave similar results (Figure 5F). We also found that both IL-4
DCs (Figure 5C) and mDCs (Figure 5G) secreted more monocyte
chemotactic protein 1 (MCP-1), macrophage inhibitory protein
1a (MIP-1a), and IL-8 in response to aLOX-1 than to control
IgG. LOX-1-activated IL-4 DCs (Figure 5D) andmDCs (Figure 5H)
also expressed more HLA-DR, CD86, and CCR7. Therefore, we
concluded that activation of DCs via LOX-1 promotes antibody-
secreting B cell responses. In particular, LOX-1-induced APRIL
and BAFF secretion from DCs plays an important role in
enhancing B cell responses, which is supported by data from
previous studies by us and others (Joo et al., 2012; Litinskiy
et al., 2002).
aDC inhibitory receptor (DCIR),aDC-specific intercellular adhe-
sion molecule-3-grabbing non-integrin (DC-SIGN), aDectin-1,
or aDEC205 mAb did not increase the amounts of APRIL or
BAFF secreted from DCs (Figure S4A). However, aDectin-1-
treated DCs slightly enhanced IgM- and IgG-, but not IgA-,
secreting B cell responses (Figure S4B). This was probably due
to the roles of cytokines, including IL-6, TNF-a, IL-1b, and IL-10,
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Figure 4. aLOX-1-Treated DCs Upregulate CCR10 but Downregulate CXCR5 on B Cells
(A) CFSE-labeled naive B cells were cocultured for 6 days with IL-4 DCs treated with either aLOX-1 or control IgG as in Figure 3A. B cells were stained for CCR10
expression.
(B) Summary of the data from eight experiments in (A). Error bars indicate SD.
(C) On day 6 of the DC-B cell cocultures, FACS-sorted CFSE B cells were added to the upper wells of transwell containing the indicated concentrations of
CCL25, CCL27, and CCL28 in the lower wells. After 2 hr, the numbers of cells that migrated into the lower wells was determined using counting beads. Results
shown are the means of three independent experiments. Error bars indicate mean ± SD of triplicate assays.
(D) Expression of CXCR5 on CFSECCR10 and CFSECCR10+ B cells cocultured with aLOX-1-treated IL-4 DCs in (A).
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LOX-1 Promotes Class-Switched B Cell Responsesthat were secreted from aDectin-1-treated DCs (Ni et al.,
2010). We further compared aLOX-1 (8B4) with three other
commercially available aLOX-1 mAbs for their ability to induce
APRIL and BAFF secretion from DCs (Figure S4C). aLOX-1
(8B4) mAb was clearly the most efficient at inducing BAFF and
APRIL from DCs.
ox-LDL Induces DCs to Secrete APRIL and BAFF,
Leading to Enhanced IgA and IgG Responses
Blood mDCs were cultured overnight in the presence of 2 mg/ml
aLOX-1 mAb or various concentrations of ox-LDL. The amounts
of APRIL and BAFF in the supernatants weremeasured by ELISA
(Figure 6A). ox-LDL (30 mg/ml) and aLOX-1 mAb (2 mg/ml)
induced similar amounts of both APRIL and BAFF secretion
from DCs. In addition, the amount of APRIL and BAFF secreted
from the DCs were ox-LDL dose-dependent. DCs activated with
either aLOX-1 or ox-LDL also expressed surface APRIL and
BAFF (Figure 6B), supporting the notion that DC-B cell interac-
tions are important for the enhanced B cell response (Figure 1F)
(Joo et al., 2012).
Figure 6C shows that both aLOX-1 and ox-LDL results in
the phosphorylation of p38 mitogen-activated protein kinase
(MAPK) and extracellular signal-regulated kinase (ERK1/2), as
well as IkBa phosphorylation in DCs. Control IgG-induced
phosphorylation of p38 and ERK at the late time points was prob-
ably due to signals via Fc receptors. Furthermore, the nuclear
factor-kappa B (NF-kB) inhibitor Wedelolactone (Carneiro
et al., 2009; Kuroda et al., 2011) blocked APRIL secretion from
the aLOX-1-treated DCs (Figure 6D).Similar to aLOX-1-treated DCs, ox-LDL-treated DCs were
able to promote B cell responses by enhancing naive B cell pro-
liferation and differentiation into PBs (Figure 6E). Blocking both
APRIL and BAFF or blocking BAFF alone in the cocultures of
ox-LDL-treated DCs and naive B cells resulted in outcomes
that were similar to those seen in the cocultures of aLOX-1-acti-
vated DCs with naive B cells (Figure 6F). aBAFF mAb mainly
decreased IgG responses. BCMA-Fc and TACI-Fc (to a lesser
extent) decreased IgA1, IgA2, and IgM. ox-LDL could also stim-
ulate B cells to secrete IgM and IgG as did aLOX-1 mAb, but the
amount of Igs secreted from B cells alone (Figure S5) was far
smaller than the amount of Igs secreted from B cells cocultured
with DCs. These data support our findings that LOX-1 plays
an important role in the DC-mediated class-switched B cell
responses in humans.
Targeting Influenza HA1 to LOX-1 Elicits HA1-Specific
Protective Antibody Responses in Macaques
We tested whether recombinant fusion proteins of influenza
HA1 and aLOX-1 mAb (aLOX-1-HA1) (Li et al., 2012) could elicit
HA1-specific protective Ab responses in rhesus macaques. The
aLOX-1 mAb was made in mice and thus does not bind to
mouse LOX-1. aLOX-1 mAb bound to rhesus macaque LOX-1
(Figure S6A). It also bound to CD11c+ and CD14+ cells, but not
CD3+ cells, in the blood of rhesusmacaques (upper, Figure S6B).
In human in vitro experiments, we also observed that aLOX-1-
HA1 could promote PB differentiation (upper, Figure S7).
Five animals were primed and boosted twice intradermally
(i.d.) with 100 mg aLOX-1-HA1, which carried approximatelyImmunity 41, 592–604, October 16, 2014 ª2014 Elsevier Inc. 597
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Figure 5. LOX-1 Induces DCs to Secrete APRIL and BAFF That Promote IgA- and IgG-Secreting B Cell Responses, Respectively
(A and E) 13 105 IL-4 DCs (A) or blood mDCs (E) were cultured 72 hr in plates coated with the indicated mAbs (2 mg/ml). The amounts of APRIL and BAFF in the
culture supernatants were assessed by ELISA. Each dot represents the data from experiments using cells from different healthy donors.
(B and F) FACS-sorted naive B cells were cocultured for 12 days with aLOX-1-activated IL-4 DCs (B) and mDCs in the presence of the indicated antibodies or
recombinant proteins (10 mg/ml). The amounts of Igs in the supernatants were measured by ELISA. Data are mean ± SD of four (B) and three (F) independent
experiments using cells from four healthy donors.
(C and G) Culture supernatants of IL-4 DCs (C) andmDCs (G) in (A) and (E) were analyzed for the amounts of chemokines by the BeadLyte cytokine assay kit. Error
bars indicate SD of three independent experiment using cells from different donors.
(D and H) Phenotypes of IL-4 DCs (D) and mDCs (H) treated with mAbs in (A) and (E).
Immunity
LOX-1 Promotes Class-Switched B Cell Responses15 mg HA1 (corresponding to the amount of HA1 for each
component of the trivalent inactivated influenza vaccine). LOX-
1+CD1c+ DCs were mainly found in the dermis of human skin
(Li et al., 2012). As shown in Figure 7A, aLOX-1-HA1 elicited
HA1-specific humoral responses, as assessed by measuring
serum hemagglutination inhibition (HAI) and virus neutralization
titers. Two animals showed HAI > 40, which is a protective in
humans. Serum antibodies in all animals could neutralize H1N1
(Cal 04) virus infection, with higher neutralization titers in the
two animals showing HAI > 40.
We next tested whether aLOX-1-HA1 could efficiently boost
HA1-specific antibody responses. Animals were challenged
with aerosolized virus particles and then boosted with 100 mg
aLOX-1-HA1 or UV-inactivated virus (53 107 pfu). Both UV-inac-
tivated virus and aLOX-1-HA1 were able to boost HA1-specific
Ab responses as assessed by measuring serum HAI (upper,
Figure 7B) and neutralization (lower, Figure 7B) titers. However,
aLOX-1-HA1 was more efficient than the UV-inactivated viruses
at boosting HA1-specific humoral responses.
We next compared the immunogenicity of aLOX-1-HA1 with
that of aDectin-1-HA1 (Figure 7D). Although aDectin-1 did not598 Immunity 41, 592–604, October 16, 2014 ª2014 Elsevier Inc.induce APRIL or BAFF expression by DCs (Figure S4A), it was
able to promote antibody responses (Figure S4B). We have
shown that aDectin-1 and aDectin-1-HA1 could induce DCs to
secrete IL-6, TNF-a, IL-1b, and IL-10, which could contribute
to B cell responses (Duluc et al., 2014; Ni et al., 2010).
aDectin-1 mAb also bound to CD11c+ and CD14+ cells in the
PBMCs of rhesus macaques (lower, Figure S6B). In this experi-
ment, we employed poly ICLC as an adjuvant because (1) it is
currently being tested in several clinical trials and (2) it could
enhance aLOX-1-HA1-induced PB differentiation in human
in vitro experiments (lower, Figure S7). Two groups of animals
were immunized with 100 mg of the proteins plus 1 mg poly
ICLC on weeks 0, 6, and 12. Animals immunized with aLOX-1-
HA1 plus poly ICLC showed higher serum HA1 titers than ani-
mals immunized with aDectin-1-HA1 plus poly ICLC (upper,
Figure 7C). Animals immunized with aLOX-1-HA1 also showed
slightly greater neutralization titers than animals immunized
with aDectin-1-HA1 (lower, Figure 7C). The same animals in
the two groups (Figure 7C) were challenged with aerosolized vi-
rus after 3 months of the second boosting. Notably, animals
immunized with aLOX-1-HA1 showed higher serum HA1 titers
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Figure 6. ox-LDL Induces Blood mDCs to Secrete APRIL and BAFF Leading to Enhanced IgA- and IgG-Secreting B Cell Responses,
Respectively
(A) 1 3 105 DCs were cultured overnight in the presence of aLOX-1 (2 mg/ml) and different concentrations of ox-LDL. The amounts of APRIL and BAFF in the
supernatants were measured by ELISA. Data are mean ± SD of three independent experiments using cells from different healthy donors.
(B) DCs were stained for surface APRIL and BAFF expression.
(C) DCswere incubated in plates coated with 2 mg/ml aLOX-1mAb or control IgG (left). DCswere incubated in the presence or absence of 30 mg/ml ox-LDL (right).
Cells were harvested at indicated time points for immunoblots. Two independent experiments showed similar results.
(D) DCs were treated first with 2 mMWedelolactone for 3 hr and then cultured for 72 hr in plates coated with aLOX-1 (2 mg/ml) or control IgG. The amount of APRIL
in the supernatants was assessed by ELISA. Error bars indicate SD of triplicate assay. Three independent experiments using cells from different donors showed
similar results.
(E) 5 3 103 blood mDCs were incubated overnight with 2 mg/ml aLOX-1 or 30 ng/ml ox-LDL. 1 3 105 FACS-sorted and CFSE-labeled naive B cells were added
and cultured for 6 days in the presence of 20 units/ml IL-2, 50 nM CpG, and 100 ng/ml agonistic aCD40 mAb. Data from four independent experiments showed
similar results.
(F) FACS-sorted naive B cells were cocultured for 12 days with aLOX-1-activated mDCs in the presence of the indicated antibodies or recombinant
proteins (10 mg/ml). The amounts of Igs in the supernatants were measured by ELISA. Data are mean ± SD of three independent experiments using cells from
three healthy donors.
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Although there was no significant difference in viral neutraliza-
tion titers in the two groups (lower, Figure 7D), two out of three
animals that received aLOX-1-HA1 showed greater neutraliza-
tion titers than the others.
Taken together, we concluded that aLOX-1-HA1 could
elicit HA1-specific antibody responses. The immunogenicity of
aLOX-1-HA1 is greatly enhanced by poly ICLC. aLOX-1-HA1
plus poly ICLC was also more efficient than aDectin-1-HA1
plus poly ICLC at eliciting HA1-specific serum antibody re-
sponses in non-human primates (NHPs).DISCUSSION
Much of the interest in LOX-1 has been focused on its involve-
ment in vascular diseases, including atherosclerosis. This is
mainly due to its expression on endothelial cells and its patho-
physiologic functions in atherosclerosis. In this study, we report
that LOX-1 expressed on DCs and B cells has functions to pro-
mote humoral immune responses.
DCs can induce and activate B cell responses in a TD and TI
fashion (Dubois et al., 1997; He et al., 2007; Jego et al., 2003;
Joo et al., 2012; Litinskiy et al., 2002; Tezuka et al., 2011; TezukaImmunity 41, 592–604, October 16, 2014 ª2014 Elsevier Inc. 599
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Figure 7. aLOX-1-HA1 Fusion Proteins Elicit HA1-Specific Protective Antibody Responses in Rhesus Macaques
(A) Five rhesus macaques were immunized i.d. with 100 mg aLOX-1-HA1 on weeks 0, 6, and 12. Serum HAI (left) and microneutralization (right) titers on weeks
0 and 14 were assessed. Each dot displays the data generated with individual macaques.
(B) Macaques were exposed with aerosolized 2.33 107 pfu of H1N1 (Cal 04) virus. At 3 months postexposure, animals were divided into two groups and boosted
i.d. with either UV-inactivated H1N1 (Cal 04) virus (53 107 pfu) or 100 mg aLOX-1-HA1. Serum HAI (upper) and microneutralization (lower) titers were measured.
(C) Macaques were primed (on week 0) and boosted twice (on weeks 6 and 12) i.d. with 100 mg aLOX-1-HA1 or aDectin-1-HA1 in combination of 1 mg poly ICLC.
Serum HAI (upper) and neutralization (lower) titers on weeks 0 and 14 were measured.
(D) Animals in (C) were challenged with aerosolized H1N1 (Cal 04) as in (A). Serum HAI (upper) and microneutralization (lower) titers were measured. Each dot
represents data generated with individual animals.
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LOX-1 Promotes Class-Switched B Cell Responseset al., 2007). DCs are able to secrete both APRIL and BAFF, and
thus can support B cell survival, proliferation, and class-switch-
ing (Joo et al., 2012; Litinskiy et al., 2002; Schneider, 2005; Stohl
et al., 2003; Xu et al., 2007). In this study, we first found that LOX-
1 can induce DCs to secrete both APRIL and BAFF, permitting
enhanced humoral immune responses. Consistent with our
previous data (Joo et al., 2012), both APRIL alone and APRIL
together with BAFF played important roles in enhancing IgM
and IgA responses. APRIL-induced IgA2 class-switching and
PB differentiation were previously reported (He et al., 2007; Litin-
skiy et al., 2002). In support of these findings, our data also
showed that TACI-Fc was more efficient at decreasing both
IgM and IgA responses than it was at decreasing IgG responses,
whereas aBAFF antibody was more efficient at decreasing IgG
responses than IgM or IgA responses (Joo et al., 2012).600 Immunity 41, 592–604, October 16, 2014 ª2014 Elsevier Inc.The ability of LOX-1 to induce DCs to express APRIL and BAFF
distinguishes it from other lectin receptors. Unlike Dectin-1,
CLEC1B, and CLEC9A, LOX-1 does not carry a known cyto-
plasmic signaling motif (YxxLx) (Geijtenbeek and Gringhuis,
2009; Hardison and Brown, 2012). However, both aLOX-1 mAb
and ox-LDL induced the activation of p38 and ERK1/2, as well
as IkBa phosphorylation in DCs. In addition, NF-kB inhibitor
(Carneiro et al., 2009; Kuroda et al., 2011) could block APRIL
secretion from aLOX-1-activated DCs, suggesting that NF-kB
activation by LOX-1 engagement plays an important role in
enhancing B cell responses. In addition, DC-SIGN does not carry
a known signaling motif, but it can activate NF-kB mainly in
conjunction with TLR2 or TLR4 (Geijtenbeek and Gringhuis,
2009). It is also known that Dectin-1 can induce MAPK and
NF-kB activation (Geijtenbeek and Gringhuis, 2009). However,
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cant amounts of APRIL or BAFF. Although both Dectin-1 and
DC-SIGN can induce IL-6 secretion by DCs (Geijtenbeek and
Gringhuis, 2009), as can LOX-1(Figure 1H), Dectin-1-activated
DCs can also secrete multiple cytokines, including IL-6, IL-1b,
TNF-a, and IL-10, as well as chemokines (Geijtenbeek and
Gringhuis, 2009; Huysamen and Brown, 2009; Ni et al., 2010),
that could further modulate downstream signaling pathways to
interfere with the expression of other proteins, including APRIL
and BAFF.
LOX-1 expressed on B cells does not greatly enhance B cell
proliferation, PB differentiation, or antibody secretion. However,
it directs B cells to upregulate CCR7, which plays an important
role in B cell migration into lymphoid tissues. CD40 plays an
essential role in B cell proliferation, class-switching, and the
development of high-affinity memory B cells (Arpin et al., 1995;
Liu and Arpin, 1997). It is also interesting to note that the expres-
sion of LOX-1 on B cells was less when B cells were activated via
three major receptors: B cell receptors (BCRs), CD40, or Toll-like
receptor 9 (TLR9). These data suggest that LOX-1 expressed on
human B cells can contribute to humoral responses.
Many of the CD11c+LOX-1+ cells localized in the marginal
zones of human spleens interact with B cells. In fact, it is known
that DCs in marginal zones can produce large amounts of APRIL
and BAFF in response to immune stimuli (MacLennan and
Vinuesa, 2002) that contribute to humoral responses, particularly
TI responses. Although the types of natural ligands for LOX-1
need to be further characterized, one can assume that LOX-
1+DCs could secrete not only APRIL and BAFF, but also IL-6
by sensing LOX-1 ligands, including ox-LDL, HSPs, and ligands
provided by different cell types, and could thus contribute
to B cell responses in a steady state. Our data generated with
poly ICLC also suggest that LOX-1 signaling can collaborate
with microbial stimuli to promote humoral responses. Elevated
serum ox-LDL concentrations and ox-LDL-mediated DC activa-
tion in systemic lupus erythematosus (SLE) patients have been
reported (Bassi et al., 2009; McMahon and Hahn, 2007). Thus,
the ox-LDL-induced DC activation could also be responsible,
at least in part, for the higher serum concentrations of APRIL
and BAFF that were followed by enhanced autoreactive B cell
responses in SLE patients.
CCR10 is known to be expressed mainly on terminally differ-
entiated B cells, as the expression of CCR10 had not been
described at any of the developmental or differentiation stages
of B cells (Bowman et al., 2000). A substantial fraction of plasma
cells derived from human bone marrow expresses CCR10 and
efficiently migrates to its ligands, CCL27 and CCL28 (Nakayama
et al., 2003). A previous study showed that the activemetabolites
of vitamin D3 could induce CCR10 expression on terminally
differentiating B cells (Shirakawa et al., 2008). In addition, a
recent study has shown that DCs in the cecal patch, but not
Peyer’s patches, can induce CCR10 on in vitro cultured murine
B cells (Masahata et al., 2014). Although it is still unclear how
LOX-1-activated DCs induce panmucosal homing receptor
CCR10 (Kunkel et al., 2003; Lazarus et al., 2003; Shirakawa
et al., 2008) on B cells, this study suggests that LOX-1 can be
a target to enhance mucosal immunity against many microbial
infections. The CCL28-CCR10 system is an important element
in the common mucosal immune system by promoting thewide distribution of locally induced IgA-secreting plasma cells
to various mucosal tissues in the body (Brandtzaeg and Johan-
sen, 2005; Kunkel et al., 2003; Lazarus et al., 2003; Shirakawa
et al., 2008).
Mucosal surfaces are themost frequent port of entry formicro-
organisms (Brandtzaeg and Johansen, 2005; Fagarasan and
Honjo, 2003). IgA, the predominant antibody isotype in mucosal
secretions, is of paramount importance in the immune defense of
these surfaces (Brandtzaeg, 2007; Renegar et al., 2004; Yel,
2010). Becausemucosal IgA is mainly secreted locally in subepi-
thelial areas, IgA-plasma cells (PC) need to acquire appropriate
homing receptors and migrate toward the effector site. Thus,
the generation of mucosal homing PCs is essential for mounting
potent immunity in local mucosa. It is also known that tissue
microenvironments where B cells undergo differentiation are
important factors that determine the expression of tissue-spe-
cific homing receptors by B cells (Mora et al., 2006; Shirakawa
et al., 2008). Therefore, it would be interesting to target LOX-1
in local mucosa to see whether it could promote mucosal
immunity in the local tissues. Nonetheless, we demonstrated
that aLOX-1 mAb fused to influenza HA1 was able to elicit pro-
tective HA1-specific Ab responses in a preclinical animal model.
In conclusion, this study demonstrates a function of LOX-1 ex-
pressed on DCs and B cells that could be applied for the design
of new vaccines against many microbial infections. Data from
this study also suggest that LOX-1 could play an important role
in the host immune responses in both healthy and diseased
states.
EXPERIMENTAL PROCEDURES
Antibodies, Reagents, and Flow Cytometry
Antibodies specific for the following molecules were used for flow cytometric
analysis and cell sorting; CD3, CD4, CD8, CD19, CD20, CD27, CD38, CD40,
CD86, CD138, and HLA-DR were from BD BioSciences. CCR6, CCR7,
CCR9, CCR10, CXCR5, and a4b7 were from R&D Systems. aCD40
(clone 12E12, in-house), aBlimp-1 (Novus Biological), aPax5 (eBioscience),
aimmunoglobulins (Southern Biotech), aAPRIL (BioLegend), and aBAFF
(R&D Systems) were used. The Live/Dead Fixable dead cell stain kit (Invitro-
gen) and the CellTrace CFSE Cell Proliferation kit (Invitrogen) were used.
Cytofix/wash buffer kit (BD) was used for an intracellular Pax5 and Blimp-1
staining. Cells were acquired on an LSRII or FACSCanto II (BD Biosciences),
and analysis was performed with FlowJo software (Tree Star). Antibodies
specific for pSTAT3 (Y705), phospho-p38, phospho-ERK, phospho-IkBa,
STAT3, p38, ERK, and IkBa were from Cell Signaling Technology. GAPDH
was from Sigma-Aldrich. ox-LDL was from BTI Biomedical Technology.
CCL19, CCL25, CCL27, and CCL28 were from eBioscience. TACI-Fc,
BCMA-Fc, and aBAFF mAb were from R&D Systems. CpG ODN2006 was
from Invivogen. Poly ICLC was provided by Dr. Andres M. Salazar (Oncovir).
Enzyme-Linked Immunosorbent Assay
Sandwich enzyme-linked immunosorbent assays (ELISAs) were performed to
measure total IgM, IgG, IgA, APRIL, and BAFF (Dullaers et al., 2009; Joo et al.,
2012), as described in Supplemental Experimental Procedures.
B Cell Morphology
B cells were stained using the DiffQuick Stain Set (Siemens) (Joo et al., 2012),
as described in Supplemental Experimental Procedures.
mAbs to C-Type Lectins
ahLOX-1 (23C11) mAb was purchased from Hycult Biotech. Clones 331212
and 331219 were from R&D Systems. Mouse mAbs specific for LOX-1 and
DC-ASGPR (Li et al., 2012), Dectin-1 (Ni et al., 2010), and DCIR (KlechevskyImmunity 41, 592–604, October 16, 2014 ª2014 Elsevier Inc. 601
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in Supplemental Experimental Procedures. aDEC-205 was provided by Dr.
Ralph Steinman (Rockefeller University). All mAbs specific for c-type lectins
contained less than 0.02 ng/ml endotoxin. 293F cells were transfected with
mock plasmid (pIRES2-DsRed2) or the same plasmid carrying hLOX-1 full
length (Li et al., 2012; Ni et al., 2010). Cells were stained with the indicated
mAbs and analyzed by flow cytometry. Recombinant fusion proteins of Fc
with hLOX-1 and hDCIR ectodomain (Klechevsky et al., 2010; Li et al., 2012)
were used to determine the specificity of aLOX-1 mAb by ELISA.
Dendritic Cells, B Cells, Medium, and Cultures
The collection of peripheral blood mononuclear cells from healthy individuals
was approved by the Institutional Review Board of Baylor Research Institute.
Blood mDCs (LinHLA-DR+CD11c+CD123) were FACS-sorted (FACSAria,
BD). Monocyte-derived IL-4 DCs, IFN DCs and TNF DCs were generated as
previously described (Ni et al., 2010). B cells were isolated using Human
B Cell Enrichment Kit (STEMCELL Technology). Naive B cells (CD19+IgD+
CD27) were sorted on a FACSAria (BD). The purity of sorted mDCs and naive
B cells was generally >98%. DC, B, DC-B, and PBMCmedium and cultures are
described in Supplemental Experimental Procedures.
Conventional and Quantitative Real-Time PCR
RNA was isolated from stimulated B cells on day 4 with Trizol (Invitrogen), and
cDNA was synthesized with Reverse Transcription System (Promega). AICDA,
switch-circle transcripts and germline and mature transcripts (Dullaers et al.,
2009; Joo et al., 2012; Litinskiy et al., 2002) were analyzed as described in
Supplemental Experimental Procedures.
Tissue Sections and Immunofluorescence
Human spleens were obtained from chronic pancreatitis patients undergoing
total pancreatectomy and splenectomy surgeries at Baylor University Medical
Center. This study was approved by the Institutional Review Board of Baylor
Research Institute. Detailed methods are described in Supplemental Experi-
mental Procedures.
Immunoblot
Cell extracts were separated by SDS-PAGE and transferred to a nitrocellulose
membrane (Bio-Rad). Immunodetection was performed by incubation with
anti-primary antibodies followed by HRP-conjugated secondary antibodies.
The bands were then visualized using the ECL chemiluminescence immuno-
blotting detection system (Amersham Biosciences).
Cytokine and Chemokine Multiplex Analysis
Cytokines and chemokines were assessed with the BeadLyte Cytokine Assay
Kit (Upstate), as per the manufacturer’s protocol. Fluorescence was analyzed
with a Bio-Plex Luminex 100 XYP instrument (Bio-Rad), with the Bio-Plex
Manager 4.1 software, with a 5-parameter curve-fitting algorithm applied for
standard curve calculations.
Recombinant Fusion Proteins of mAbs and HA1 Antigens
Recombinant fusion proteins of aLOX-1-HA1 and aDectin-1-HA1 were made
as described (Duluc et al., 2014; Li et al., 2012). Detailed methods are
described in Supplemental Experimental Procedures.
Animals, Immunization, Viral Challenge, and SerumAntibody Assays
Male rhesus macaques (Macaca mulatta) (4–5 years old) weighing 4–8 kg were
used. All animal experiments were conducted at the Tulane National Primate
Research Center (TNPRC), with the approval of the Animal Care and Use
Committees at the Baylor Research Institute and TNPRC. Hemagglutination
inhibition andmicroneutralization assays were performed at a BSL3 laboratory
as previously described. Detailed methods are described in Supplemental
Experimental Procedures.
Statistical Analysis
All bar graphs represent mean ± SD. Data were analyzed with GraphPad Prism
4 software. The significance of difference between experimental variables was
determined using the Student’s t test and ANOVA. The significance was set at
p < 0.05.602 Immunity 41, 592–604, October 16, 2014 ª2014 Elsevier Inc.SUPPLEMENTAL INFORMATION
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